Shares of Cancer Genetics Inc (NASDAQ:CGIX) shot up 10% during mid-day trading on Wednesday . The company traded as high as $0.36 and last traded at $0.33. 553,427 shares were traded during mid-day trading, an increase of 77% from the average session volume of 312,127 shares. The stock had previously closed at $0.30.

A number of research firms have issued reports on CGIX. HC Wainwright set a $3.00 target price on Cancer Genetics and gave the stock a “buy” rating in a research report on Wednesday, August 15th. Maxim Group reissued a “hold” rating on shares of Cancer Genetics in a research report on Tuesday, August 14th. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $4.50.

The stock has a market capitalization of $12.53 million, a PE ratio of -0.42 and a beta of 1.10. The company has a debt-to-equity ratio of 0.03, a current ratio of 0.66 and a quick ratio of 0.66.

An institutional investor recently raised its position in Cancer Genetics stock. Renaissance Technologies LLC increased its stake in Cancer Genetics Inc (NASDAQ:CGIX) by 15.0% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 675,200 shares of the medical research company’s stock after purchasing an additional 87,900 shares during the quarter. Renaissance Technologies LLC owned about 2.43% of Cancer Genetics worth $702,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 13.55% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was originally published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another website, it was copied illegally and reposted in violation of United States & international trademark and copyright legislation. The original version of this story can be accessed at

Cancer Genetics Company Profile (NASDAQ:CGIX)

Cancer Genetics, Inc engages in the development, commercialization, and sale of molecular and biomarker-based tests and services. Through its Select One Clinical Trials program, the firm provides a range of clinical trial services for both oncology and non-oncology genetic testing such as bioinformatics, biomaker solutions, biorepository solutions, consulting, cytogenetics testing, nucleic acid extraction and purification, flow cytometry, Focus::NGS Panel, gene expression analyses, genotyping, and pharmacogenomics.

Featured Story: What is a Candlestick Chart?

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with's FREE daily email newsletter.